"Although making strides in Phase 1 - almost all biotech is bought out at phase 2."
Whilst that's true, we have seen multi-billion dollar takeovers of pre-clinical assets.
It all depends on what you have I guess.
Also, if you are a big phama looking at cf33, do you decided to wait until phase 2 data comes out and the whole world (and your fierce competition) knows about it?
Strike first in my opinion.
Ann: Imugene Investor Webinar - MAST Study Update, page-171
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.1¢ |
Change
-0.001(0.70%) |
Mkt cap ! $527.0M | |||
| Open | High | Low | Value | Volume |
| 7.2¢ | 7.4¢ | 7.0¢ | $549.1K | 7.655M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 43 | 1966224 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.1¢ | 738374 | 20 |
View Market Depth
| Last trade - 13.31pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.1¢ |
Change
-0.001 ( 1.95 %) |
||||
| Open | High | Low | Volume | ||
| 7.2¢ | 7.3¢ | 7.0¢ | 4698182 | ||
| Last updated 13.51pm 15/05/2024 ? | |||||
| IMU (ASX) Chart |